Effects of Pausing and Re‐Initiating Fremanezumab After Continuous 24‐Month Treatment for Preventing Difficult‐To‐Treat Migraine: Prospective, Multicenter, Real‐World Data From the <scp>GRASP</scp> Study Group
Discontinuation of fremanezumab after month 24 leads to rising MMD/MHDs. After fremanezumab re-initiation, a relatively reduced effectiveness in the first 3 months might occur, compared with the pre-fremanezumab cessation. Overall, our findings doubt the rationale behind mandated anti-CGRP treatment pauses in migraine prophylaxis.
Authors
- Aikaterini Foska (ORCID: https://orcid.org/0000-0002-5164-4952)
- Maria Chondrogianni (ORCID: https://orcid.org/0000-0002-8315-5846)
- Dimitrios Rikos (ORCID: https://orcid.org/0000-0003-2346-5057)
- Georgia Xiromerisiou (ORCID: https://orcid.org/0000-0001-7162-3588)
- Georgios K. Tsivgoulis (ORCID: https://orcid.org/0000-0002-0640-3797)
- Panagiotis Soldatos
- Michail Vikelis (ORCID: https://orcid.org/0000-0002-2715-7898)
- Eleni Mavraki
- Andreas A. Argyriou (ORCID: https://orcid.org/0000-0003-2131-7114)
- Pantelis Litsardopoulos
- Emmanouil V. Dermitzakis (ORCID: https://orcid.org/0000-0001-9275-0076)
Institutions
- University of Thessaly (GR)
- Democritus University of Thrace (GR)
- National and Kapodistrian University of Athens (GR)
- Agios Andreas Hospital (GR)
- Technological Educational Institute of Peloponnese (GR)
- General Confederation of Greek Workers (GR)
- Euromedica (GR)
- University General Hospital Attikon (GR)
- Base Training (GR)
- 404 General Military Hospital (GR)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1111/ene.70327
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47